Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new clinical and real-world data from its cardiovascular (CV) portfolio presented at the American ...

Hypertension is believed to be the single greatest factor influencing the development of heart failure, particularly heart failure with preserved ejection fraction, also known as diastolic heart ...

TEWKSBURY, Mass.--(BUSINESS WIRE)--DC Devices, Inc., a medical device company pioneering first-in-class structural heart devices, has closed a $34 million Series D financing round. Accelmed led the ...

For the first time in the U.S., a clinical trial is underway that's evaluating a device designed to treat diastolic heart failure. The first patient enrolled in the randomized, blinded study is being ...

Researchers at the University of Colorado School of Medicine have identified a potential treatment target for patients with a common type of heart failure. (HealthDay)—Diabetes and prediabetes ...

Diastolic dysfunction increasingly is recognized as an important cause of congestive heart failure (CHF). In this study, Mayo Clinic researchers surveyed a random sample of 2042 adults (age, 45 or ...

Orchestra BioMed Holdings, Inc. announced promising echocardiographic data regarding atrioventricular interval modulation (AVIM) therapy's impact on patients with diastolic dysfunction at the THT 2025 ...

M ore than 6 million adults in the United States have heart failure. Of these, about half have diastolic heart failure and the other half have systolic heart failure. In February 2021, the U.S. Food ...

For the first time in the U.S., a clinical trial is underway that's evaluating a device designed to treat diastolic heart failure. The first patient enrolled in the randomized, blinded study is being ...

Please provide your email address to receive an email when new articles are posted on . An AI algorithm for detection of grade 3 diastolic dysfunction received a breakthrough device designation from ...